SMS Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹316 Cr +30.6% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
SP

SMS Pharmaceuticals Ltd

Q3 FY26Pharmaceuticals & Biotechnology

SMS Pharmaceuticals Q3 FY26: Revenue ₹210.45 Cr, PAT ₹23.47 Cr

Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹210Cr
+21.4% YoY
−13.2% QoQ
Net profit
₹23Cr
+27.8% YoY
−8% QoQ
Margin
21%
+2 pp YoY
+1 pp QoQ

Based on SMS Pharmaceuticals Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹474
Market cap₹4.1K Cr
P/E40.5

The short version

Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] - Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY [Page 6, 27] - Q3FY26 PAT after MI & Associate: ₹23.47 cror Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY - Q3FY26 EBITDA Margin: 21%, up 158 basis points YoY - Q3FY26 PAT: ₹23.47 crore, up 29% YoY - Q3FY26 PAT Margin: 11%, improved by 63 basis p

From SMS Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27]
  • Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY [Page 6, 27]
  • Q3FY26 PAT after MI & Associate: ₹23.47 crore, up 29% YoY [Page 27]
  • EPS for Q3FY26: ₹2.59, up 20% YoY [Page 27, 6]
  • Volume growth noted as a key driver for revenue increase; strong volume growth in key APIs highlighted [Page 5]

2 more points from SMS Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Total capex spend planned: ₹280 crore, to be completed by FY27 (Page 25).
  • Capex oriented towards:
  • Capacity expansion for existing APIs.
  • Building capacities for a new API pipeline.
  • Land acquisition underway for a greenfield project (Page 25).
  • Capex project mix: 89% brownfield (capacity expansion), 11% greenfield (new plant) (Page 25).
  • Strategic focus post last 3-4 years' capex cycle is on asset utilization to deliver high-teen returns (Page 25).

2 more points from SMS Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what SMS Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

SMS Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

SMS Pharmaceuticals Ltd Q3 FY26 results — key figures

SMS Pharmaceuticals Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue210173+21.4%242-13.2%
Operating profit (EBITDA)4433+33.3%48-8.3%
Operating margin21%19%+2 pp20%+1 pp
Profit before tax3122+40.9%34-8.8%
Net profit (PAT)2318+27.8%25-8%
EPS (₹)2.512.15+16.7%2.70-7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹316 Cr, net profit ₹40 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

SMS Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were SMS Pharmaceuticals Ltd Q3 FY26 results?

Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] - Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY [Page 6, 27] - Q3FY26 PAT after MI & Associate: ₹23.47 cror Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY - Q3FY26 EBITDA Margin: 21%, up 158 basis points YoY - Q3FY26 PAT: ₹23.47 crore, up 29% YoY - Q3FY26 PAT Margin: 11%, improved by 63 basis p

What is SMS Pharmaceuticals Ltd share price analysis?

SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹4,148 Cr. Investors should review the full earnings analysis for detailed insights.

Is SMS Pharmaceuticals Ltd planning capital expenditure?

Total capex spend planned: ₹280 crore, to be completed by FY27 (Page 25).

Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.